Zenpep patents expiration
1. Zenpep patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562979 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8246950 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | ZENPEP | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562978 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US7658918 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2014 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 27 August, 2013
Market Authorisation Date: 25 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
More Information on Dosage
ZENPEP family patents
